Finished products

As a generic company Egis PLC primarily produces and markets such generic products that can help in providing a more cost-effective therapy than the originator for a greater number of patients. Our products are market leaders in several countries and many of our generic patents have been acknowledged by an innovation prize.

In the 2010/2011 financial year we marketed 135 product lines containing 117 active ingredients and our product portfolio altogether contained 520 products. Our most important therapeutic areas are the cardiovascular, the central nervous and the respiratory systems: the sales revenue of these three groups accounted for 74% of our human pharmaceutical sales. Products acting on blood forming organs gave 7% of our sales, whereas drugs acting on the alimentary tract and the metabolism accounted for 6.4%.

It is our strategic goal to expand the number of products we produce and market and the therapeutic areas, therefore oncology and OTC products are becoming more and more significant. As a result, the sales and share of our oncology products increased by 19% in 2010/2011 compared to the previous year.

In the 2010/2011 financial year, 29 product lines achieved sales figures over HUF 1 billion. The turnover of four product lines exceeded HUF 6 billion, and the largest turnover was achieved by our perindopril product line licensed from Servier, followed by our chloropyramine and metoprolol product families.

Our visitors can receive information about our OTC products at www.egisvenynelkul.hu while, upon registration, www.egismed.hu provides detailed professional information about our prescription medicines exclusively for healthcare professionals.